S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
A Bio-Tech Stock That Has Been Growing Like Crazy! (Ad)
Federal student loan payments are starting again. Here's what you need to know
Facing increasing pressure from customers, some miners are switching to renewable energy
A Bio-Tech Stock That Has Been Growing Like Crazy! (Ad)
Rishi Sunak needs to rally his flagging Conservatives. He hopes a dash of populism will do the trick
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
The World's First "$20 Trillion Drug (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Grant program for Black women entrepreneurs blocked by federal appeals court
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
A Bio-Tech Stock That Has Been Growing Like Crazy! (Ad)
Federal student loan payments are starting again. Here's what you need to know
Facing increasing pressure from customers, some miners are switching to renewable energy
A Bio-Tech Stock That Has Been Growing Like Crazy! (Ad)
Rishi Sunak needs to rally his flagging Conservatives. He hopes a dash of populism will do the trick
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
The World's First "$20 Trillion Drug (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Grant program for Black women entrepreneurs blocked by federal appeals court
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
A Bio-Tech Stock That Has Been Growing Like Crazy! (Ad)
Federal student loan payments are starting again. Here's what you need to know
Facing increasing pressure from customers, some miners are switching to renewable energy
A Bio-Tech Stock That Has Been Growing Like Crazy! (Ad)
Rishi Sunak needs to rally his flagging Conservatives. He hopes a dash of populism will do the trick
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
The World's First "$20 Trillion Drug (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Grant program for Black women entrepreneurs blocked by federal appeals court
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
A Bio-Tech Stock That Has Been Growing Like Crazy! (Ad)
Federal student loan payments are starting again. Here's what you need to know
Facing increasing pressure from customers, some miners are switching to renewable energy
A Bio-Tech Stock That Has Been Growing Like Crazy! (Ad)
Rishi Sunak needs to rally his flagging Conservatives. He hopes a dash of populism will do the trick
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
The World's First "$20 Trillion Drug (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Grant program for Black women entrepreneurs blocked by federal appeals court
NASDAQ:AMPH

Amphastar Pharmaceuticals (AMPH) Stock Forecast, Price & News

$45.99
-1.31 (-2.77%)
(As of 09/29/2023 ET)
Compare
Today's Range
$45.68
$47.70
50-Day Range
$45.51
$65.00
52-Week Range
$26.76
$67.66
Volume
524,136 shs
Average Volume
616,318 shs
Market Capitalization
$2.22 billion
P/E Ratio
23.58
Dividend Yield
N/A
Price Target
$70.50

Amphastar Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
53.3% Upside
$70.50 Price Target
Short Interest
Bearish
7.40% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.21
Upright™ Environmental Score
News Sentiment
0.62mentions of Amphastar Pharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$5.51 M Sold Last Quarter
Proj. Earnings Growth
30.00%
From $2.50 to $3.25 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.76 out of 5 stars

Medical Sector

67th out of 970 stocks

Pharmaceutical Preparations Industry

16th out of 448 stocks


AMPH stock logo

About Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API). It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation; and Vasopressin to increase blood pressure in adults with vasodilatory shock. Further, the company distributes recombinant human insulin APIs and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

AMPH Price History

AMPH Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)
“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”
Ironwood Pharma (IRWD) Receives a Buy from Piper Sandler
Five IBD 50 Stocks In Trouble
Q2 2023 Amphastar Pharmaceuticals Inc Earnings Call
Lilly Pops on Sales
See More Headlines
Receive AMPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amphastar Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMPH Company Calendar

Last Earnings
8/08/2023
Today
10/01/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AMPH
Employees
1,615
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$70.50
High Stock Price Forecast
$71.00
Low Stock Price Forecast
$70.00
Forecasted Upside/Downside
+53.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$91.39 million
Pretax Margin
24.08%

Debt

Sales & Book Value

Annual Sales
$498.99 million
Cash Flow
$2.37 per share
Book Value
$10.94 per share

Miscellaneous

Free Float
34,561,000
Market Cap
$2.22 billion
Optionable
Optionable
Beta
0.84
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Ziping Luo Ph.D. (Age 73)
    Chairman, Chief Scientist & COO
    Comp: $1.53M
  • Dr. Yongfeng  Zhang Ph.D.Dr. Yongfeng Zhang Ph.D. (Age 76)
    Co-Founder, Pres, CEO, Chief Scientific Officer & Director
    Comp: $2.13M
  • Mr. William J. Peters M.B.A.Mr. William J. Peters M.B.A. (Age 55)
    CFO, Exec. VP of Fin., Treasurer & Director
    Comp: $1.12M
  • Mr. Jacob Liawatidewi M.B.A. (Age 49)
    Exec. VP of Sales, Marketing & Corp. Admin. Center, Corp. Sec. and Director
    Comp: $794.15k
  • Mr. Rong Zhou M.S. (Age 64)
    Sr. Exec. VP of Production
    Comp: $835.05k
  • Dan Dischner M.B.A.
    VP of HR & Corp. Communication
  • Tony Marrs M.B.A.
    M.P.H., Sr. VP of Regulatory Affairs & Clinical Operations













AMPH Stock - Frequently Asked Questions

Should I buy or sell Amphastar Pharmaceuticals stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AMPH shares.
View AMPH analyst ratings
or view top-rated stocks.

What is Amphastar Pharmaceuticals' stock price forecast for 2023?

2 brokerages have issued twelve-month target prices for Amphastar Pharmaceuticals' shares. Their AMPH share price forecasts range from $70.00 to $71.00. On average, they predict the company's share price to reach $70.50 in the next twelve months. This suggests a possible upside of 53.3% from the stock's current price.
View analysts price targets for AMPH
or view top-rated stocks among Wall Street analysts.

How have AMPH shares performed in 2023?

Amphastar Pharmaceuticals' stock was trading at $28.02 at the beginning of the year. Since then, AMPH shares have increased by 64.1% and is now trading at $45.99.
View the best growth stocks for 2023 here
.

Are investors shorting Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 2,690,000 shares, an increase of 106.9% from the August 31st total of 1,300,000 shares. Based on an average trading volume of 457,500 shares, the days-to-cover ratio is presently 5.9 days. Approximately 7.4% of the shares of the company are sold short.
View Amphastar Pharmaceuticals' Short Interest
.

When is Amphastar Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our AMPH earnings forecast
.

How were Amphastar Pharmaceuticals' earnings last quarter?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) issued its earnings results on Tuesday, August, 8th. The company reported $0.58 EPS for the quarter, topping analysts' consensus estimates of $0.52 by $0.06. The business earned $145.71 million during the quarter, compared to the consensus estimate of $137.20 million. Amphastar Pharmaceuticals had a net margin of 18.85% and a trailing twelve-month return on equity of 20.12%.

What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO?

35 employees have rated Amphastar Pharmaceuticals Chief Executive Officer Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among the company's employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at Amphastar Pharmaceuticals to a friend.

What other stocks do shareholders of Amphastar Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT).

What is Amphastar Pharmaceuticals' stock symbol?

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

How do I buy shares of Amphastar Pharmaceuticals?

Shares of AMPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amphastar Pharmaceuticals' stock price today?

One share of AMPH stock can currently be purchased for approximately $45.99.

How much money does Amphastar Pharmaceuticals make?

Amphastar Pharmaceuticals (NASDAQ:AMPH) has a market capitalization of $2.22 billion and generates $498.99 million in revenue each year. The company earns $91.39 million in net income (profit) each year or $1.95 on an earnings per share basis.

How many employees does Amphastar Pharmaceuticals have?

The company employs 1,615 workers across the globe.

How can I contact Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The official website for the company is www.amphastar.com. The company can be reached via phone at (909) 980-9484, via email at jasons@amphastar.com, or via fax at 909-980-8296.

This page (NASDAQ:AMPH) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -